Who invested in AgomAB Therapeutics

2 rounds we have observed, with the 10 investors named in them. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

BiotechHealthcare

Funding summaryUpdated 26 Oct 2026

$112Mraised across 2 rounds since 2019, from 2 sources

$24MSeries A$89MSeries D

Latest round: Series D, $89MOct 2024
Step-upi: 3.8×
Investors: 10 (2 led)

See who backed them

The funding story

Each circle is a round, placed by date and sized by amount. The line above is the running total.

201920202021202220232024

$24MSeries A$89MSeries D

First round: Series A, $24M
Biggest round: $89M
Between rounds: 5.5 years

The rounds

Oct 2024
Series D$89M5 new
Source recorded
Apr 2019
Series A$24M5 new
- V-Bio VenturesLead
- Advent France BiotechnologyLead
- Omnes
- Boehringer Ingelheim
- Pontifax
Reported by FinSMEs

Founders and team

From AgomAB Therapeutics's own website: 11 on the team.

Tim KnotnerusChief Executive Officer
Andrea SáezChief Development Officer
Paul van der HorstChief Business Officer
Philippe WieselChief Medical Officer
Pierre KemulaChief Financial Officer
Angelika JahreisNon-Executive Director
Colin BondNon-Executive Director and Chairman of the Audit Committee.
David EpsteinChairman of the Board
Ellen LefeverGeneral Counsel
Marino GarciaNon-Executive Director
Naimish PatelNon-Executive Director

Who was in which round

The busiest backers across the latest rounds. A filled square is a round they joined; a dark one, a round they led.

Series A2019Series D2024

V-Bio VenturesLAdvent France BiotechnologyL

Canaan

Cormorant Asset Management

Omnes

Sanofi

EQT Life Sciences

Andera PartnersBoehringer IngelheimPontifax

Everyone who backed them

V-Bio VenturesVC firm1round, led 1

Advent France BiotechnologyVC firm1round, led 1

CanaanVC firm1round

Cormorant Asset ManagementPrivate equity1round

OmnesVC firm1round

SanofiInvestment firm1round

EQT Life SciencesVC firm1round

Andera PartnersPrivate equity1round

Boehringer IngelheimVC firm1round

Pontifaxno record of our own yet1round

Missing a round, or an investor who was in one? Tell us.

Also claim to have backed them

This firm lists AgomAB Therapeutics as a portfolio company on their own website, but no report of a round names it. They are the firms' own claims, kept apart from the rounds above.

AdBio partnersVC firmPer its own site

Quick answers about AgomAB Therapeutics

Who invested in AgomAB Therapeutics?

AgomAB Therapeutics's investors include V-Bio Ventures, Advent France Biotechnology, Canaan, Cormorant Asset Management and Omnes, and 5 more on record.